Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab Long-Term Extension Study in Moderate to Severe Hidradenitis Suppurativa
NCT04901195Phase 3Completed
- Sponsor
- UCB
- Start
- May 2021
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of bimekizumab in hidradenitis suppurativa (HS) (2 arms), sponsored by UCB. Primary endpoint: Treatment-Emergent Adverse Events. Started May 2021; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04901195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901195.